Evaluating the clinical performance of SDC2/NDRG4 methylation for colorectal cancer detection

The performance and clinical accuracy of combined methylation were evaluated in diagnosing colorectal cancer (CRC) and advanced adenoma. A total of 2333 participants were enrolled to assess the sensitivity and specificity of biomarkers in diagnosing CRC in a multicenter clinical trial through feces DNA methylation tests. methylation showed excellent performance for CRC detection in biomarker research and the real world. Its sensitivity for detecting CRC, early CRC and advanced adenoma were 92.06%, 91.45% and 62.61%, respectively. Its specificity was 94.29%, with a total coincidence rate of 88.28%. When interference samples were included, the specificity was still good (82.61%). Therefore, the methylation test showed excellent performance in detecting CRC and advanced adenoma under clinical application.